From the publishers of JADPRO
HR+ HER2- Breast Cancer
Resource Center
Menu
Resources
Videos
Videos
Quizzes
News & Literature Highlights
Case Studies
Advertisement
Test your knowledge on HR-positive, HER2-negative breast cancer
Last Updated: Friday, August 15, 2025
Loading...
Advertisement
News & Literature Highlights
The Breast
Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy
Scientific Reports
Increased primary breast tumor expression of CD73 is associated with development of bone metastases and is a potential biomarker for adjuvant bisphosphonate use
Frontiers in Oncology
Cryoablation in the treatment of early breast cancer: A comprehensive analysis
JAMA Oncology
Breast cancer index in premenopausal women with early-stage hormone receptor–positive breast cancer
Anticancer Research
Cardioprotective effect of pegfilgrastim on chemotherapy-induced cardiotoxicity in preoperative chemotherapy for breast cancer
The Breast
Systematic literature review and trial-level meta-analysis of aromatase inhibitors vs tamoxifen in patients with HR+/HER2- early breast cancer
Cancers (Basel)
CDK4/6 as a therapeutic target in HR+/HER2- breast cancer cells—Current treatment status
Clinical Cancer Research
Identification of early-stage breast cancer with minimal risk of recurrence by Breast Cancer Index
Journal of Clinical Oncology
INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC)
Journal of Clinical Oncology
VERITAC-2: A global, randomized phase 3 study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer
Advertisement
Case Studies
Isolated Brain Metastasis in BRCA2-Mutated HR+ HER2- Breast Cancer
Genetic Testing and Risk Intervention Based on Family History of Early-Onset Breast Cancer
First-Line Treatment for Metastatic ER+ HER2- Breast Cancer
Advertisement
Quizzes
Test your knowledge of isolated brain metastasis in BRCA2-mutated HR+ HER2- breast cancer
Test your knowledge of genetic testing and risk intervention based on family history of early-onset breast cancer
Test your knowledge on HR-positive, HER2-negative breast cancer